Bone-targeting treatments have transformed the quality of life of patients with metastatic bone disease. 2011 saw the emergence of denosumab—a RANK ligand-specific antibody—as a more-effective alternative treatment to bisphosphonates and of data on the use of bone-targeting treatments to prevent metastasis from breast and prostate cancers.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis
Nature Cell Biology Open Access 09 November 2023
-
Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation
Journal of Nanobiotechnology Open Access 22 July 2021
-
Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
Journal of Hematology & Oncology Open Access 23 February 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Stopeck, A. T. et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J. Clin. Oncol. 28, 5132–5139 (2010).
Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).
Henry, D. H. et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J. Clin. Oncol. 29, 1125–1132 (2011).
Saad, F. et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active-controlled phase III trials in cancer patients with bone metastases. Ann. Oncol. http://dx.doi.org/10.1093/annonc/mdr435.
Parker, C. et al. Overall survival benefit of radium-223 chloride (alpharadin) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomised trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47 (Suppl. 2), a3 (2011).
Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679–691 (2009).
Gnant, M. et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 12, 631–641 (2011).
Gnant, M. et al. Overall survival with adjuvant zoledronic acid in patients with premenopausal breast cancer with complete endocrine blockade: Long-term results from ABCSG-12 [abstract]. J. Clin. Oncol. 29 (Suppl. 15), a520 (2011).
Coleman, R. E. et al. Breast-cancer adjuvant therapy with and without zoledronic acid. N. Engl. J. Med. 365, 1396–1405 (2011).
Smith, M. R. et al. Denosumab and bone metastasis-free survival in men with castration-resistant prostate cancer: results of a global phase 3, randomised, placebo-controlled trial. Lancet http://dx.doi.org/10.1016/S0140-6736(11)61226-9.
Author information
Authors and Affiliations
Ethics declarations
Competing interests
R. E. Coleman declares that he has received honoraria from Amgen and Novartis. He has also received a research grant from and was on the advisory board of Novartis.
Rights and permissions
About this article
Cite this article
Coleman, R. Prevention and treatment of bone metastases. Nat Rev Clin Oncol 9, 76–78 (2012). https://doi.org/10.1038/nrclinonc.2011.198
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrclinonc.2011.198
This article is cited by
-
MAF amplification licenses ERα through epigenetic remodelling to drive breast cancer metastasis
Nature Cell Biology (2023)
-
Chiral nanomaterials for tumor therapy: autophagy, apoptosis, and photothermal ablation
Journal of Nanobiotechnology (2021)
-
Coexistence of brown tumors due to secondary hyperparathyroidism and prostate cancer in a patient
Osteoporosis International (2021)
-
Role of the bone microenvironment in bone metastasis of malignant tumors - therapeutic implications
Cellular Oncology (2020)
-
Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer
Journal of Hematology & Oncology (2018)